Clinical Trials Logo

Dandruff clinical trials

View clinical trials related to Dandruff.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06436495 Completed - Dandruff Clinical Trials

Methodology Validation: Correlating Adherent Scalp Flaking Score (ASFS) With Phototrichogram for Scalp Dandruff Evaluation in Adult Subjects

Start date: May 22, 2024
Phase: N/A
Study type: Interventional

This study aims to validate methods for assessing scalp hair dandruff by comparing three evaluation techniques: the Adherent Scalp Flaking Score (ASFS), Phototrichogram, and 60-second hair combing. These assessments will be conducted before and after hair wash interventions on adult human subjects to evaluate adherent and non-adherent scalp flakes. By comparing the results of these evaluations, the study aims to determine the consistency and reliability of each method in assessing the presence and severity of dandruff. Establishing correlation between these assessment techniques is essential for validating their usefulness in evaluating the effectiveness of hair care products and treatments in reducing scalp dandruff. This research aims to improve the accuracy and reliability of dandruff evaluation methods, benefiting both dermatological research and clinical practice in managing this prevalent condition.

NCT ID: NCT06052241 Completed - Folliculitis Clinical Trials

Artificial Intelligence-based Prescription of Personalized Scalp Cosmetics

Start date: July 27, 2021
Phase: N/A
Study type: Interventional

The investigators aimed to evaluate whether they can be improved by an AI-based personalized prescription of scalp cosmetics.

NCT ID: NCT05989633 Completed - Dandruff Clinical Trials

DERCOS DS DANDRUFF TREATMENT OBSERVATIONAL STUDY 2022

Start date: July 4, 2022
Phase:
Study type: Observational

The aim of this study is to evaluate the satisfaction / tolerance / cosmeticity of Dercos DS

NCT ID: NCT02448082 Completed - Dandruff Clinical Trials

The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis

Start date: October 2014
Phase: Phase 2
Study type: Interventional

Dandruff, also known as Pityriasis capitis, is a common condition which affects the scalp of almost half the post-pubertal population regardless of race and gender. It is said that dandruff affects at least 50% of the world's adult population and about 15 - 20% of the world's total population. Dandruff is usually marked by flaking as well as itching and irritation of the scalp which can also lead to greasiness. Dandruff can lead to physiological and psychological issues and can be very distressing and embarrassing for the sufferer, causing low self esteem and social problems. Current treatment options for dandruff include many over-the-counter preparations, anti-dandruff shampoos and topical steroid applications which are accompanied by numerous adverse effects. According to Lunar Pharmaceuticals Ichthyol® Pale is a sodium salt of pale sulphonated shale oil in aqueous solution with anti-microbial properties which can combat dandruff helping with the causative and symptomatic relief of this condition. The aim of the study is to determine the efficacy of Sodium Shale Oil Sulponate 1% shampoo in the treatment of Pityriasis capitis. This will be evaluated using the Adherent Scalp Flaking Score (ASFS) grading and the Visual Analogue Scale (VAS).

NCT ID: NCT01388517 Completed - Pityriasis Alba Clinical Trials

Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba

Start date: January 2008
Phase: Phase 4
Study type: Interventional

Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, trend to relapse and aesthetic impact. Currently, no treatment is widely accepted. The objective is to assess the calcitriol and tacrolimus ointment efficacy in the treatment of PA compared with petrolatum. Twenty lesions on the face greater than 3 cm, in individuals of phototype IV-V, aged 3-18 years are going to be randomly assigned to receive petrolatum, calcitriol, and tacrolimus twice daily. No photoprotection is going to be indicated, and hygienic habits will not be modified. Patients will be evaluated at baseline and for 9 weeks, by means of Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.